HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients

In non-small-cell lung cancer (NSCLC), sensitivity to tyrosine kinase inhibitors (TKIs) is associated with activating mutations and genomic gain of the epidermal growth factor receptor (EGFR). Preclinical data suggested that HER3 overexpression increases sensitivity to TKIs. A total of 82 NSCLC pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Cappuzzo, F, Toschi, L, Domenichini, I, Bartolini, S, Ceresoli, G L, Rossi, E, Ludovini, V, Cancellieri, A, Magrini, E, Bemis, L, Franklin, W A, Crino, L, Bunn, P A, Hirsch, F R, Varella-Garcia, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361531/
https://www.ncbi.nlm.nih.gov/pubmed/16288303
http://dx.doi.org/10.1038/sj.bjc.6602865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361531/
https://www.ncbi.nlm.nih.gov/pubmed/16288303
http://dx.doi.org/10.1038/sj.bjc.6602865

Ejemplares similares